📰 Nasdaq Edit News
Page 6 - Nasdaq Edit News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Edit. Real-time updates on events, politics, business and more.
February 27, 2023
Pictet Asset Management SA lifted its stake in Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 37.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 182,186 shares of the company’s stock after purchasing an additional 49,782 shares during the quarter. Pictet Asset Management […]
February 27, 2023
Pictet Asset Management SA raised its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 37.6% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 182,186 shares of the company’s stock after purchasing an additional 49,782 shares during the period. Pictet Asset Management SA […]
February 22, 2023
Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter On track to provide...
November 4, 2022
Editas Medicine (NASDAQ:EDIT – Get Rating) had its price target reduced by investment analysts at Chardan Capital from $60.00 to $43.00 in a report issued on Wednesday, The Fly reports. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s price objective would suggest a potential upside of 268.47% from the stock’s previous […]
July 26, 2022
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will...
June 14, 2022
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) shares hit a new 52-week low during trading on Tuesday . The company traded as low as $9.68 and last traded at $9.68, with a volume of 1376 shares trading hands. The stock had previously closed at $10.00. A number of research analysts recently commented on EDIT shares. […]
June 7, 2022
Equities analysts predict that Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) will post sales of $5.32 million for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Editas Medicine’s earnings, with the lowest sales estimate coming in at $2.20 million and the highest estimate coming in at $10.00 million. Editas Medicine […]
June 7, 2022
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) EVP Bruce Eaton sold 1,123 shares of the firm’s stock in a transaction on Friday, June 3rd. The stock was sold at an average price of $11.54, for a total transaction of $12,959.42. Following the completion of the sale, the executive vice president now owns 65,421 shares of […]
June 6, 2022
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) CFO Michelle Robertson sold 1,527 shares of Editas Medicine stock in a transaction that occurred on Friday, June 3rd. The stock was sold at an average price of $11.54, for a total value of $17,621.58. Following the completion of the sale, the chief financial officer now owns 82,667 […]
May 22, 2022
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) has been assigned an average recommendation of “Hold” from the eleven analysts that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The […]